ApoA-I mimetic peptides with differing ability to inhibit atherosclerosis also exhibit differences in their interactions with membrane bilayers.

Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus.

Expression of CCL20 and granulocyte-macrophage colony-stimulating factor, but not Flt3-L, from modified vaccinia virus ankara enhances antiviral cellular and humoral immune responses.

Atherosclerosis and vascular disease: effects of peptide mimetics of apolipoproteins.

Potential clinical utility of high-density lipoprotein-mimetic peptides.

Probing the possibilities for T-cell-based AIDS vaccines.

Synthetic peptides: managing lipid disorders.

Is 'chemo-fog'/'chemo-brain' caused by cancer chemotherapy?

Oral amphipathic peptides as therapeutic agents.

An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice.

Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide.

D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice.

Apolipoprotein A-I mimetic peptides.

Apolipoprotein E mimetic Peptide dramatically lowers plasma cholesterol and restores endothelial function in watanabe heritable hyperlipidemic rabbits.

Divergent host responses during primary simian immunodeficiency virus SIVsm infection of natural sooty mangabey and nonnatural rhesus macaque hosts.